



Published in final edited form as:

Int J Cancer. 2018 June 15; 142(12): 2425–2434. doi:10.1002/ijc.31215.

Impaired functional vitamin B6 status is associated with increased risk of lung cancer

A full list of authors and affiliations appears at the end of the article.

Abstract

Circulating vitamin B6 levels have been found to be inversely associated with lung cancer. Most studies have focused on the B6 form pyridoxal 5'-phosphate (PLP), a direct biomarker influenced by inflammation and other factors. Using a functional B6 marker allows further investigation of the potential role of vitamin B6 status in the pathogenesis of lung cancer. We prospectively evaluated the association of the functional marker of vitamin B6 status, the 3-hydroxykynurenine:xanthurenic acid ratio (HK:XA), with risk of lung cancer in a nested case-control study consisting of 5,364 matched case control pairs from the Lung Cancer Cohort Consortium (LC3). We used conditional logistic regression to evaluate the association between HK:XA and lung cancer, and random effect models to combine results from different cohorts and regions. High levels of HK:XA, indicating impaired functional B6 status, were associated with an increased risk of lung cancer, the odds ratio comparing the fourth and the first quartiles (OR_{4th vs 1st}) was 1.25 [95% confidence interval, 1.10-1.41]. Stratified analyses indicated that this association was primarily driven by cases diagnosed with squamous cell carcinoma. Notably, the risk associated with HK:XA was approximately 50% higher in groups with a high relative frequency of squamous cell carcinoma, i.e. men, former and current smokers. This risk of squamous cell carcinoma was present in both men and women regardless of smoking status.

Keywords

Pyridoxal 5'-phosphate; Functional vitamin B6 marker; 3-hydroxykynurenine:xanthurenic acid; Lung cancer cohort consortium

Introduction

Lung cancer is the most common cause of cancer related death, contributing to almost 20% of all cancer deaths worldwide¹. The four major histological types of lung cancer are adenocarcinomas, squamous cell carcinomas, large cell carcinomas, and small cell carcinomas. The most important risk factor for lung cancer is smoking, but the strength of the association depends on the type of lung cancer². Some lung cancer types like small cell and squamous cell carcinomas occur almost exclusively due to smoking, while others, like adenocarcinomas, also occur frequently in non-smokers².

*Corresponding author: Bjorn.Midttun@uib.no, phone: +47 55 97 46 04. Adress: Postboks 7804, 5020 Bergen Norway.

Competing interests

LMB is an employee of Genetech Inc. as of September 16.

Vitamin B6 may play a role in carcinogenesis, since it is involved in DNA synthesis, methylation, and repair³, chromosomal stability⁴ and oxidative stress⁵. Indeed, circulating B6 measured as pyridoxal 5'-phosphate (PLP) was found to be inversely associated with lung cancer risk in two earlier case control studies, nested in prospective cohorts^{6,7}, but in a recent analysis within the Lung Cancer Cohort Consortium (LC3), vitamin B6 was found to be only marginally associated with cancer risk in former and current smoking men⁸.

However, circulating levels of the vitamin B6 measure used in these papers, the widely used PLP, are influenced by factors other than vitamin B6 status. These factors include inflammation, alkaline phosphatase activity, low serum albumin and renal function⁹, and reduce the usefulness of PLP as a marker of vitamin B6 status.

A recently established functional marker of vitamin B6 status is the ratio of circulating levels of two metabolites in the kynurenine pathway of tryptophan metabolism, 3-hydroxykynurenine (HK) and xanthurenic acid (XA), i.e. HK:XA [4]. The conversion of HK to XA is catalyzed by the PLP-dependent enzyme kynurenine aminotransferase, while the formation of HK does not require PLP¹⁰. The substrate-product ratio HK:XA has been shown to increase in B6 deficient individuals and reduced to normal levels after supplementation with B6¹⁰.

Given the drawbacks of PLP as a marker of vitamin B6 status, the aim of the present study was to use the functional vitamin B6 marker HK:XA to further investigate the role of vitamin B6 status as a predictor of lung cancer risk. The study used data from over 5,000 cases-controls pairs from the Lung Cancer Cohort Consortium (LC3), nested within 20 prospective cohorts from the USA, Europe, Asia and Australia.

Methods

Study population

All prospective cohort studies within the National Cancer Institute (NCI) Cancer Consortium were invited to participate in the study. Twenty cohorts, from USA (11 cohorts), Europe (total of 4 cohorts from Norway, Sweden, and Finland), Asia (4 cohorts consisting of Chinese populations residing in Shanghai and Singapore) and Australia (1 cohort), fulfilled the inclusion criteria (having cryopreserved baseline plasma or serum samples, and being members of the US National Cancer Institute (NCI) Cohort Consortium in 2009) and accepted to participate. Details on design of the cohorts and their follow-up procedures have been previously published⁸.

Selection of cases and controls

Lung cancer cases were defined on the basis of the International Classification of Diseases for Oncology, Second Edition (ICD-O-2) and included invasive cancers coded as C34.0-C34.9. From the 11,399 incident lung cancer cases with pre-diagnostic blood samples, 5,545 cases were selected by oversampling never and former smoking cases. For each case, one control was randomly chosen from risk-sets consisting of all cohort members alive and free of cancer (except non-melanoma skin cancer) at the time of diagnosis of the index case. Matching criteria were cohort, sex, date of blood collection, and date of birth. Controls were

also matched by smoking status at time of blood collection in 5 categories; never smokers, short and long term quitters among former smokers (<10 years, 10 years since quitting), and light and heavy smokers among current smokers (< 15, 15 cigarettes per day). In total, 5,364 lung cancer case-control pairs were eligible for inclusion after excluding cases who were not correctly matched on smoking status (n=124), who had insufficient plasma sample volume for analysis of biomarkers (n=42), or had a revised date of diagnosis prior to blood draw (n=13)⁸.

Biochemical analyses

Analysis of all serum or plasma samples was performed in the Bevital A/S laboratory (<http://www.bevital.no>) in Bergen, Norway. Concentrations of HK, XA, PLP and cotinine, a marker of recent nicotine exposure¹¹ were determined using a liquid chromatography–tandem MS assay¹², and C-reactive protein (CRP) was analysed by immuno-MALDI-MS¹³ in batches of 86 samples. Quality control procedures included 6 calibration plasma, 2 control plasma, and 1 blank sample (water) in each batch. All blood samples were stored at –80°C or lower until analysis and cases and their matched controls were analyzed together within the same batches in random order, with laboratory staff blinded to case-control status. Further details on the biochemical analyses have been published elsewhere⁸.

Statistical analysis

We used conditional logistic regression (conditioning on individual case sets) to calculate the odds ratios (OR) with 95% confidence intervals (CI) for lung cancer according to levels of HK:XA. The analysis was adjusted for smoking intensity using quartiles of cotinine concentrations based on the distribution of cotinine among current smokers. We performed analyses within each cohort, comparing the fourth to the first quartile (OR_{4th vs 1st}) of HK:XA. Results were combined for each region (United States [USA], Europe, Asia, Australia), and for the overall study population by using random effects models. Heterogeneity across subgroups was quantitatively assessed by the Q-test and I² index¹⁴.

We further performed stratified analyses for sex, smoking category (never, former, and current smokers), histology of lung cancer (by HK:XA tertiles), and time between blood sample collection and diagnosis. Due to the large differences in vitamin status between regions¹⁵, quartiles (or tertiles) of concentrations for each biomarker were based on the distribution among controls by region. We additionally used conditional logistic regression for calculating the odds ratio for lung cancer across quartiles by region and for the total population, using the first quartile as reference. Quartiles were included as a continuous variable to calculate p for trend.

In supplementary analysis stratified by histology in addition to smoking status or sex we included HK:XA as a continuous variable, using the base-2 logarithm (log₂) of the biomarker in a conditional logistic regression model. Estimates from this model may be interpreted as the relative risk associated with a doubling in circulating biomarker concentration. Partial Spearman correlations adjusted for age and sex were used to describe the association between HK:XA and PLP, and both biomarkers with cotinine. All statistical

analyses were conducted using R 3.2.2 for Macintosh¹⁶. The package “survival”¹⁷ was used for conditional logistic regression, and package “metafor” for forestplots¹⁸.

Results

Study population

The final study population included 5,364 lung cancer cases and 5,364 matched controls, with a median age of 62 years at blood sample collection (Table 1). Median time between blood draw and lung cancer diagnosis was 6.3 years. Of the total study population, 46% of the participants were women. At baseline, nearly half of the participants were current smokers, and one fourth were former, and never smokers, respectively (Table 1). Due to different inclusion criteria in the original cohorts, five cohorts (Health Professionals Follow-up Study, Physicians Health Study, ATBC, The Shanghai Cohort Study and The Shanghai Mens' Health Study) included only men, and five cohorts (WHI, NYUWHS, WHS, NHS and SWHS) only women (Figure 1). The prevalence of smoking also differed substantially between cohorts (Figure 1).

Determinants of HK:XA within the LC3

HK:XA varied somewhat across regions, (median values ranging from 2.88 to 3.28 among controls) with the lowest level among Australian controls and the highest among Europeans. Larger variations were observed for plasma PLP, with the highest concentrations in the controls from US cohorts (median 49.9 nmol/L) and the lowest concentrations among the European cases, at 28.1 nmol/L. We observed an inverse relation between HK:XA and PLP (Spearman $\rho = -0.37$), while smoking was essentially not associated with HK:XA ($\rho = 0.11$), but was inversely related to plasma PLP ($\rho = -0.30$) (all $p < 0.001$).

HK:XA and lung cancer

Random effects models were used to investigate the relation of HK:XA with risk of lung cancer across geographic regions because the heterogeneity by cohort varied significantly across the geographic regions (Supplemental Table S1). Overall, high levels of HK:XA (4th vs. 1st quartile) were associated with a 25% increased risk for lung cancer (Figure 2). However, results differed across regions with positive associations observed in Europe, with an odds ratio comparing the fourth and the first quartiles (95% confidence interval) of 1.43 (1.06, 1.95), and the USA 1.31 (1.05, 1.62), but no association in Asia or Australia (Figure 2). Results were similar when using quartiles based on the distribution of each region, instead of cohort specific cut-offs (Supplemental Table S2).

The weakest associations were observed in cohorts that included only women. When those cohorts (The Women's Health Initiative, The New York University Women's Health Study, Women's Health Study and Nurses Health Study) were excluded, the association of HK:XA with risk of lung cancer in the USA was similar, 1.41 (1.15, 1.46), to that seen in Europe. Additional adjustment for CRP, a marker for systemic inflammation, did not attenuate the risk association for HK:XA (data not shown).

Analyses stratified by sex and smoking

In analysis stratified by sex the overall association between HK:XA and lung cancer risk was primarily seen among men, with a 50% increased risk of lung cancer when comparing fourth vs. first quartile (Figure 3). No significant association was observed for women, (p heterogeneity = 0.01 and $I^2 = 62.4\%$, Supplemental Table S3). Smoking habits differed between sexes, with the proportion of never smokers much higher among women (Figure 1). A similar effect modification was present for smoking categories, with the association between HK:XA and lung cancer limited to current and former smokers (p for heterogeneity = 0.18, $I^2 = 30.1\%$, Supplemental Table S4) (Figure 4).

Histology of lung cancer

Histology of lung cancer differed according to smoking status, with squamous cell carcinoma being more common among current and former smokers (28% and 20% respectively, compared to 6% among never smokers) and in men compared to women (29% vs. 10%). In analysis according to histology of lung cancer in the overall population, HK:XA was related to an increased risk for squamous cell carcinoma OR (95% CI) 1.42 (1.10, 1.82) for 3rd vs. 1st tertile, but not with other histological types (data not shown).

This association with HK:XA and squamous cell carcinoma was consistently present in subgroup analysis by both sex and smoking status. Specifically, for a continuous log₂ model, representing a doubling of HK:XA concentrations, the OR (95% CI) was 1.20 (1.02, 1.41) in men, 1.59 (1.20, 2.10) in women (Supplemental Figure S2). In current smokers the OR (95% CI) was 1.22 (1.02, 1.46), in former smokers 1.37 (1.08, 1.73), and in never smokers 1.59 (0.90, 2.80), even though in this last group the confidence interval was quite wide due to the low number of cases (Supplemental figure S1).

Time to diagnosis

In analysis stratified by time to diagnosis, the association was limited to participants who were diagnosed with lung cancer within 36 months from blood draw, OR_{log₂} (95% CI) 1.43 (1.27, 1.61) for a doubling in the concentration of HK:XA. No significant association between HK:XA and lung cancer risk was observed for those with a longer time between blood draw and diagnosis (p for heterogeneity <0.001).

Discussion

Main findings

High levels of HK:XA, indicating an impaired functional vitamin B6 status, were associated with an increased risk of lung cancer. In stratified analysis the risk of lung cancer was approximately 50% higher for those in the highest category of HK:XA in men, and in former and current smokers, but not significant in women or never smokers. In analysis stratified by histology HK:XA was associated with an increased risk of squamous cell carcinoma, but not other histological types. When histopathology subtype of lung cancer was considered, a consistent association was found for squamous cell carcinoma regardless sex and smoking status. The lack of association of HK:XA with overall lung cancer among

women and never smokers could be at least partly attributed to the low number of cases of squamous cell carcinoma in those strata of the present study population.

Comparison with previous findings

Overall, our findings are in agreement with published results on the B6 vitamers PLP and cancer risk¹⁹, even though stronger inverse associations were noted in relation to lung cancer in the EPIC⁶ and ATBC⁷ studies. Concordant with the current study, we recently observed an inverse association of PLP with lung cancer risk in LC3, an association that was primarily confined to former and current smoking men⁸.

We observed a positive association between HK:XA and risk of squamous cell carcinoma, but no significant association with other histological types of lung cancer. This observation is also in line with a previous observation of an inverse association between plasma PLP and risk of cancer primarily classified as squamous cell carcinoma⁸.

In EPIC an inverse association of PLP on lung cancer was also observed in never smokers, but the number of cases that were never smokers was low (n=96)⁶, and this results should be viewed with caution.

In a previous cohort study where PLP and HK:XA were simultaneously assessed as predictors of cancer no clear association was found for any of the two markers. However, this study had limited statistical power due to the small number of cases (n_{cases}=85)²⁰.

HK:XA as a marker of vitamin B6 status and predictor of lung cancer

There are consistent reports on plasma PLP as a predictor of cancer in the lungs^{6, 7} and other organs¹⁹. Plasma PLP is the most commonly used marker of vitamin B6 status, but plasma PLP concentrations are reduced by several factors linked to lung cancer carcinogenesis or progression, such as smoking²¹, inflammation measured as CRP²²⁻²⁴, and increased level of alkaline phosphatase²⁵. On the other hand, inflammation and elevated alkaline phosphatase (ALP) are not associated with impaired vitamin B6 availability in tissues⁹.

Smoking is associated with lower levels of PLP, and vitamin B6 status gradually improves over years after smoking cessation²⁶. In contrast, smoking shows no or a weak association with the HK:XA ratio¹⁰, an observation confirmed in the present study. In the current study, cases and controls were matched for smoking status and we additionally adjusted for smoking intensity, using circulating cotinine concentrations. We cannot exclude residual confounding by smoking, but since the association between HK:XA and lung cancer was also present in former smokers, confounding by smoking is unlikely.

CRP is inversely associated with plasma PLP^{27, 28} but shows a weak positive association with HK:XA¹⁰. After additional adjustment for CRP, the risk estimates of HK:XA and lung cancer remained essentially the same, suggesting no or minor confounding from inflammation. Elevated ALP may reduce PLP through conversion to pyridoxal (PL)⁹, but HK and XA are not substrates for ALP, and one would not expect any direct effects from ALP on the plasma levels of these metabolites.

Similarly to the findings on PLP in the LC3 study⁸, the association between HK:XA and lung cancer was stronger among participants with a short time between blood draw and diagnoses.

Therefore, it is possible that the observed association between HK:XA and risk may reflect impaired vitamin B6 status due to pre-clinical changes in lung cancer.

Strengths and limitations of the study

The present study is based on an unprecedented sample of 5,364 pre-diagnostic blood samples from lung cancer cases with comparable control samples recruited in 20 prospective cohorts from around the world. The prospective study design minimizes the risk of reverse causality and selection bias. The use of a centralized laboratory with a stringent quality control protocols and cases and matched controls analyzed together minimizes any technical differential bias, and an overrepresentation of never and former smokers provided adequate power for stratified analysis. By using a functional marker that is largely independent on factors that are related to circulating PLP, we found a clear inverse relation of vitamin B6 status with risk of lung cancer.

There was only one blood sample available for measurement of biomarkers for each participant, so the association between HK:XA and lung cancer may be attenuated due to regression dilution bias. It is possible that depending on the time of the blood draw and the length of study follow-up, the single measurement may not represent the exposure period most relevant for lung cancer development. Lastly, information on the histology of lung cancer was missing for 34 % of the participants.

Conclusions

Our findings provide evidence for an inverse association of functional vitamin B6 status and risk of lung cancer, especially squamous cell carcinoma. This expands our understanding beyond what can be concluded from the modest relation observed for the direct vitamin B6 marker PLP⁸, circulating levels of which is influenced by factors other than vitamin B6 status, in this same study. It is recommended that future studies strive for a sample size large enough to provide the power necessary for analysis stratified by duration of follow-up, smoking and histology given the potential differences of the role of vitamin B6 in pathogenesis and progression of different histological cancer types.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Despoina Theofylaktopoulos¹, Øivind Midttun^{2,*}, Per M. Ueland^{1,3}, Klaus Meyer², Anouar Fanidi^{4,5}, Wei Zheng⁶, Xiao-Ou Shu⁶, Yong-Bing Xiang^{6,7}, Ross Prentice⁸, Mary Pettinger⁸, Cynthia A. Thomson⁹, Graham G Giles^{11,12}, Allison Hodge^{11,12}, Qiuyin Cai⁶, William J. Blot⁶, Jie Wu⁶, Mikael Johansson¹², Johan Hultdin¹³, Kjell Grankvist¹³, Victoria L. Stevens¹⁴, Marjorie M. McCullough¹⁴, Stephanie J.

Weinstein¹⁵, Demetrius Albanes¹⁵, Regina Ziegler¹⁵, Neal D. Freedman¹⁵, Arnulf Langhammer¹⁶, Kristian Hveem¹⁶, Marit Næss¹⁶, Howard D. Sesso^{17,18,19}, J. Michael Gaziano¹⁸, Julie E. Buring^{17,19}, I-Min Lee^{17,19}, Gianluca Severi^{21,22}, Xuehong Zhang²³, Meir J. Stampfer^{23,24,25}, Jiali Han²⁴, Stephanie A. Smith-Warner^{24,25}, Anne Zeleniuch-Jacquotte²⁶, Loic le Marchand²⁷, Jian-Min Yuan^{28,29}, Renwei Wang²⁸, Lesley M. Butler^{28,29}, Woon-Puay Koh³⁰, Yu-Tang Gao³¹, Nathaniel Rothman³², Ulrika Ericson³³, Emily Sonestedt³³, Kala Visvanathan³⁴, Miranda R. Jones³⁴, Caroline Relton^{35,36}, Paul Brennan⁴, Mattias Johansson⁴, and Arve Ulvik²

Affiliations

¹Department of Clinical Science, University of Bergen, Norway

²Bevital AS, Bergen, Norway

³Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway

⁴Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France

⁵MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom

⁶Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, USA

⁷Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

⁸Division of Public Health Sciences, Fred Hutchinson Cancer research Center, Seattle, USA

⁹Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA

¹⁰Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia

¹¹Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia

¹²Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden

¹³Department of Medical Biosciences, Umeå University, Umeå, Sweden

¹⁴Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA

¹⁵Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

¹⁶HUNT Research Centre, Department of Public Health and Nursing, Faculty of Medicine and Health Science, NTNU, Norwegian University of Science and Technology, Trondheim, Norway

- ¹⁷Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA
- ¹⁸Division of Aging, Brigham and Women's Hospital, Boston, MA USA
- ¹⁹Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- ²⁰VA Boston Healthcare System, Boston, MA USA
- ²¹Human Genetics Foundation (HuGeF), Torino, Italy
- ²²CESP (U1018 INSERM), Facultés de médecine Université Paris-Sud, UVSQ, Université Paris-Saclay, Villejuif, France
- ²³Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- ²⁴Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
- ²⁵Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- ²⁶Department of Population Health, New York University School of Medicine, USA
- ²⁷Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA
- ²⁸Division of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
- ²⁹Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
- ³⁰Duke-NUS Medical School, Singapore and Saw Swee Hock School of Public Health, National University of Singapore, Singapore
- ³¹Department of Epidemiology, Shanghai Cancer Institute, Shanghai Jiaotong University, Shanghai, China
- ³²Division of Cancer Epidemiology & Genetics, Occupational and Environmental Epidemiology Branch, National Cancer Institute; Rockville, USA
- ³³Department of clinical sciences Malmö, Lund University, Sweden
- ³⁴Johns Hopkins Bloomberg School of Public Health and Johns Hopkins Sidney Kimmel Comprehensive Center, School of Medicine, USA
- ³⁵Institute of Genetic Medicine, Newcastle University, Newcastle, UK
- ³⁶MRC Integrative Epidemiology Unit, School of Social & Community Medicine, University of Bristol, Bristol, UK

Acknowledgments

The Lung Cancer Cohort Consortium (LC3) was supported by NIH/NCI grant 1U01CA155340-01 and Australian National Health and Medical Research Committee grant 1050198. SWHS was/is supported by R37 CA070867 and

UM1 CA182910, SMHS by R01 CA082729 and UM1 CA173640 from the U.S. National Cancer Institute. SCCS is supported by R01 CA092447 and U01 CA202979 from the U.S. National Cancer Institute. The Multiethnic Cohort Study was funded in part by grant U01 CA164973. The ATBC Study is supported by the Intramural Research Program of the U.S. National Cancer Institute, National Institutes of Health, and by U.S. Public Health Service contract HHSN261201500005C from the National Cancer Institute, Department of Health and Human Services. CLUE thank the participants and staff for their contributions, as well as the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Department of Health and Mental Hygiene, 201 W. Preston Street, Room 400, Baltimore, MD 21201, <http://phpa.dhmh.maryland.gov/cancer>, 410-767-4055. CLUE acknowledge the State of Maryland, the Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries of the Centers for Disease Control and Prevention for the funds that support the collection and availability of the cancer registry data. The Prostate Lung Colorectal Ovarian Cancer Screening Trial (PLCO) is supported by contracts from the Division of Cancer Prevention and intramural research funding from the Division of Cancer Epidemiology and Genetics, National Cancer Institute, U.S. National Institutes of Health (NIH), Department of Health and Human Services (DHHS). PLCO was supported by the National Institutes of Health (NIH) grants, UM1CA167552, UM1CA186107, P01CA87969, and R01CA49449. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. CR is supported by CRUK (C18281/A19169) and the Medical Research Council Integrative Epidemiology Unit at the University of Bristol with funds from the MRC (MC_UU_12013/2) and the University of Bristol. The funding organizations had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript.

Abbreviations

PLP	pyridoxal 5'-phosphate
HK:XA	3-hydroxykynurenine:xanthurenic acid
CI	confidence interval
EPIC	European Prospective Investigation into Cancer and Nutrition
ATBC	Alpha-Tocopherol, Beta-Carotene Cancer Prevention
OR	odds ratio
LC3	Lung Cancer Cohort Consortium


References

1. Ferlay, J., S, I., Ervik, M., Dikshit, R., et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11. GLOBOCAN 2012 v1.0. Lyon, France: International Agency for Research on Cancer; 2013.
2. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. *Lung Cancer*. 2001; 31:139–48. [PubMed: 11165392]
3. Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. *Mutat Res*. 2001; 475:7–20. [PubMed: 11295149]
4. Ames BN, Wakimoto P. Are vitamin and mineral deficiencies a major cancer risk? *Nat Rev Cancer*. 2002; 2:694–704. [PubMed: 12209158]
5. Wondrak, GT., Jacobson, EL. Vitamin B6: Beyond Coenzyme Functions. In: Stanger, O., editor. *Water Soluble Vitamins: Clinical Research and Future Applicationed*. Dordrecht: Springer Netherlands; 2012. p. 291-300.
6. Johansson M, Relton C, Ueland PM, et al. Serum B vitamin levels and risk of lung cancer. *JAMA*. 2010; 303:2377–85. [PubMed: 20551408]
7. Hartman TJ, Woodson K, Stolzenberg-Solomon R, et al. Association of the B-vitamins pyridoxal 5'-phosphate (B(6)), B(12), and folate with lung cancer risk in older men. *Am J Epidemiol*. 2001; 153:688–94. [PubMed: 11282797]

8. Fanidi A, Muller D, Yuan JM, et al. Circulating Folate, Vitamin B6 and Methionine in relation to Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3). *Journal of the national cancer institute*. 2017 In press.
9. Ueland PM, Ulvik A, Rios-Avila L, et al. Direct and Functional Biomarkers of Vitamin B6 Status. *Annu Rev Nutr*. 2015; 35:33–70. [PubMed: 25974692]
10. Ulvik A, Theofylaktopoulos D, Middtun O, et al. Substrate product ratios of enzymes in the kynurenine pathway measured in plasma as indicators of functional vitamin B-6 status. *Am J Clin Nutr*. 2013; 98:934–40. [PubMed: 24004893]
11. Seccareccia F, Zuccaro P, Pacifici R, et al. Serum Cotinine as a Marker of Environmental Tobacco Smoke Exposure in Epidemiological Studies: The Experience of the MATISS Project. *Eur J Epidemiol*. 2003; 18:487–92. [PubMed: 12908713]
12. Middtun Ø, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. *Rapid Communications in Mass Spectrometry*. 2009; 23:1371–9. [PubMed: 19337982]
13. Meyer K, Ueland PM. Targeted Quantification of C-Reactive Protein and Cystatin C and Its Variants by Immuno-MALDI-MS. *Anal Chem*. 2014; 86:5807–14. [PubMed: 24848523]
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002; 21:1539–58. [PubMed: 12111919]
15. Middtun O, Theofylaktopoulos D, McCann A, et al. Circulating concentrations of biomarkers and metabolites related to vitamin status, one-carbon and the kynurenine pathways in US, Nordic, Asian, and Australian populations. *Am J Clin Nutr*. 2017; 105:1314–26. [PubMed: 28424186]
16. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2105.
17. T, T. A Package for Survival Analysis in S_. version 2.38. 2015. <URL: <https://CRAN.R-project.org/package=survival>>
18. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *Journal of Statistical Software*. 2010; 36:1–48.
19. Mocellin S, Briarava M, Pilati P. Vitamin B6 and Cancer Risk: A Field Synopsis and Meta-Analysis. *J Natl Cancer Inst*. 2017; 109
20. Zuo H, Ueland PM, Eussen SJ, et al. Markers of vitamin B6 status and metabolism as predictors of incident cancer: the Hordaland Health Study. *Int J Cancer*. 2015; 136:2932–9. [PubMed: 25404109]
21. Doll R, Hill AB. Lung Cancer and Other Causes of Death in Relation to Smoking. *Br Med J*. 1956; 2:1071–81. [PubMed: 13364389]
22. Shiels MS, Katki HA, Hildesheim A, et al. Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification. *J Natl Cancer Inst*. 2015; 107
23. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. *Crit Rev Clin Lab Sci*. 2011; 48:155–70. [PubMed: 22035340]
24. Bittoni MA, Focht BC, Clinton SK, et al. Prospective evaluation of C-reactive protein, smoking and lung cancer death in the Third National Health and Nutrition Examination Survey. *Int J Oncol*. 2015; 47:1537–44. [PubMed: 26323323]
25. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. *Eur Respir J*. 1994; 7:1350–64. [PubMed: 7925916]
26. Ulvik A, Ebbing M, Hustad S, et al. Long- and Short-term Effects of Tobacco Smoking on Circulating Concentrations of B Vitamins. *Clin Chem*. 2010; 56:755–63. [PubMed: 20299681]
27. Sakakeeny L, Roubenoff R, Obin M, et al. Plasma Pyridoxal-5-Phosphate Is Inversely Associated with Systemic Markers of Inflammation in a Population of U.S. Adults. *J Nutr*. 2012; 142:1280–5. [PubMed: 22623384]
28. Shen J, Lai C-Q, Mattei J, et al. Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: the Boston Puerto Rican Health Study. *Am J Clin Nutr*. 2010; 91:337–42. [PubMed: 19955400]

Novelty and Impact

Low vitamin B6 status, assessed by circulating pyridoxal 5'-phosphate (PLP), has been associated with increased risk of lung cancer. However, factors other than vitamin B6 status may contribute to lower PLP, possibly confounding its association with lung cancer. In the present study we demonstrated, by using a novel functional biomarker of B6 status that impaired functional vitamin B6 status was associated with increased risk of lung cancer, especially squamous cell carcinoma.

**Figure 1.**

Panel A. Distribution of smoking status stratified by sex in the different regions. Panel B. Distribution of smoking status and sex in the different cohorts. ATBC, The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CLUE, The Campaign Against Cancer and Stroke (CLUE I) and the Campaign Against Cancer and Heart Disease (CLUE II); CPS-II, The American Cancer Society Cancer Prevention Study-II Nutrition Cohort; HPFS, Health Professionals Follow-up Study; HUNT, The Nord-Trøndelag Health Study; MCCS, The Melbourne Collaborative Cohort Study; MDCS, The Malmö Diet and Cancer Study; MEC, The Multiethnic Cohort; NHS, The Nurses' Health Study; NSHDS, The Northern Sweden Health and Disease Study Cohort; NYUWHS, The New York University Women's Health Study; PHS, Physicians' Health Study; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SCCS, The Southern Community Cohort Study; SCHS, The Singapore Chinese Health Study; SCS, The Shanghai Cohort Study; SMHS, The Shanghai Men's Health Study; SWHS, The Shanghai Women's Health Study; WHI, The Women's Health Initiative; WHS, Women's Health Study.





Figure 2. Forestplot showing odds ratios for lung cancer comparing the fourth to the first quartile of HK:XA. Conditional logistic regression was performed for each cohort and was adjusted for smoking intensity using quartiles of cotinine among current smokers. Cases and controls were matched on age, sex, and smoking status. Results were combined using random effect models for each region and in all studies combined. HK:XA, 3-hydroxykynurenine:xanthurenic acid.

**Figure 3.**

Forestplot showing odds ratios for lung cancer comparing the fourth to the first quartile of HK:XA in the different regions, stratified by gender. Conditional logistic regression was performed for each region and was adjusted for smoking intensity using quartiles of cotinine among current smokers. Cases and controls were matched on age, sex, and smoking status. Results were combined using random effect models. HK:XA, 3-hydroxykynurenine:xanthurenic acid.




Figure 4. Forestplot showing odds ratios for lung cancer comparing the fourth to the first quartile of HK:XA in the different regions, stratified by smoking status. Conditional logistic regression was performed for each subgroup and among current smokers (adjusted for smoking intensity using quartiles of cotinine among current smokers). Cases and controls were matched for age, sex, and smoking status. Results were combined using random effect models. HK:XA, 3-hydroxykynurenine:xanthurenic acid.

Table 1

Baseline and clinical characteristics of study participants overall and according to region¹

Characteristics	Overall			Asian cohorts		Australian cohort		European cohorts		USA cohorts	
	Controls (n=5364)	Cases (n=5364)		Controls (n=1775)	Cases (n=1775)	Controls (n=354)	Cases (n=354)	Controls (n=835)	Cases (n=835)	Controls (n=2400)	Cases (n=2400)
Age ² (years)	62 (47–75)	62 (47–75)		62 (46–74)	62 (46–74)	61 (45–67)	61 (45–67)	60 (45–71)	60 (45–71)	64 (48–78)	64 (48–78)
Sex											
Men	2908 (54%)	2908 (54%)		1229 (69%)	1229 (69%)	213 (60%)	213 (60%)	475 (57%)	475 (57%)	991 (41%)	991 (41%)
Women	2456 (46%)	2456 (46%)		546 (31%)	546 (31%)	141 (40%)	141 (40%)	360 (43%)	360 (43%)	1409 (59%)	1409 (59%)
Smoker											
Never	1327 (25%)	1327 (25%)		602 (34%)	602 (34%)	49 (14%)	49 (14%)	107 (13%)	107 (13%)	569 (24%)	569 (24%)
Former	1518 (28%)	1518 (28%)		176 (10%)	176 (10%)	145 (41%)	145 (41%)	190 (23%)	190 (23%)	1007 (42%)	1007 (42%)
Current	2519 (47%)	2519 (47%)		997 (56%)	997 (56%)	160 (45%)	160 (45%)	538 (64%)	538 (64%)	824 (34%)	824 (34%)
Biomarkers											
HK:XA	2.98 (1.39–7.70)	3.13 (1.44–8.49)		3.01 (1.52–7.09)	3.10 (1.58–7.98)	2.88 (1.45–6.68)	3.00 (1.34–7.55)	3.08 (1.58–7.08)	3.28 (1.64–9.13)	2.93 (1.27–8.24)	3.13 (1.29–8.98)
HK (nmol/L)	36.6 (20.3–70.6)	37.1 (20.1–74.5)		38.7 (21.9–81.6)	39.6 (22.4–85.4)	36.0 (22.1–65.8)	37.8 (21.3–69.3)	37.2 (21.6–63.9)	38.3 (23.1–67.2)	34.8 (18.9–65.2)	34.7 (18.2–66.2)
XA (nmol/L)	12.4 (4.6–29.1)	11.9 (4.3–28.7)		13.5 (5.4–29.9)	13.0 (5.1–29.2)	12.4 (4.9–26.5)	12.9 (5.2–29.4)	11.9 (5.1–26.5)	11.4 (4.5–27.1)	11.8 (4.2–29.4)	11.1 (3.9–29.1)
PLP (nmol/L)	37.1 (13.9–197)	35.1 (12.5–204)		30.8 (12.3–118)	28.9 (11.0–114)	31.3 (14.3–110)	31.3 (14.2–207)	30.9 (13.1–101)	28.1 (12.5–104)	49.9 (16.4–271)	47.6 (15.2–266)
Clinical characteristics											
Age at diagnosis (years)	69.8 (53.6–82.0)	69.8 (53.6–82.0)		69 (52–80)	69 (52–80)	70 (56–78)	70 (56–78)	68 (53–81)	68 (53–81)	70 (55–83)	70 (55–83)
Time to diagnosis ³ (years)	6.3 (1.0–16.0)	6.3 (1.0–16.0)		5.8 (0.7–16.5)	5.8 (0.7–16.5)	9.7 (1.3–16.2)	9.7 (1.3–16.2)	10.0 (1.8–16.1)	10.0 (1.8–16.1)	5.2 (1–15.5)	5.2 (1–15.5)
Histology											
Large cell carcinoma	174 (3%)	174 (3%)		16 (1%)	16 (1%)	31 (9%)	31 (9%)	15 (2%)	15 (2%)	112 (5%)	112 (5%)
Small cell carcinoma	492 (9%)	492 (9%)		99 (6%)	99 (6%)	47 (13%)	47 (13%)	103 (12%)	103 (12%)	245 (10%)	245 (10%)
Squamous cell carcinoma	836 (16%)	836 (16%)		319 (18%)	319 (18%)	67 (19%)	67 (19%)	162 (19%)	162 (19%)	291 (12%)	291 (12%)
Adenocarcinoma	2056 (39%)	2056 (39%)		615 (35%)	615 (35%)	153 (43%)	153 (43%)	260 (31%)	260 (31%)	1034 (43%)	1034 (43%)
Missing/Unknown	1806 (34%)	1806 (34%)		726 (41%)	726 (41%)	56 (16%)	56 (16%)	295 (35%)	295 (35%)	735 (31%)	735 (31%)

¹ Characteristics are presented as n (%) for discrete variables and median (5th, 95th percentile) for continuous variables

² At blood collection

³ Time from blood draw to diagnosis

HK:XA, 3-hydroxykynurenine;xanthurenic acid; PLP, pyridoxal 5',-phosphate

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript